Phase 0 1 trial
Phase 0
NCT04424966 Jul 2020 → Jan 2023 glioblastoma Nader Sanai
Terminated
No outcome recorded
Phase 1 7 trials
Phase 1
NCT05510427 Aug 2023 cholangiocarcinoma M.D. Anderson Cancer Center
Withdrawn
No outcome recorded
Phase 1
NCT04972253 Dec 2021 → Dec 2022 bladder transitional cell carcinoma Guru P. Sonpavde
Withdrawn
No outcome recorded
Phase 1
NCT04504331 Oct 2020 → Oct 2021 Her2-receptor negative breast cancer , estrogen-receptor positive breast cancer , progesterone-receptor positive breast cancer Jennifer Lee Caswell-Jin
Terminated
No outcome recorded
Phase 1
NCT02312804 Jan 2015 cervical carcinoma The University of Texas Health Science Center at San Antonio
Withdrawn
No outcome recorded
Phase 1
NCT01928459 Oct 2013 → Aug 2016 cancer , metastatic neoplasm Novartis Pharmaceuticals
Completed
No outcome recorded
Phase 1
NCT01697605 Oct 2012 → Feb 2019 —
Novartis Pharmaceuticals
Completed
No outcome recorded
Phase 1
NCT01004224 Dec 2009 → Oct 2018 squamous cell lung carcinoma , urinary bladder cancer Novartis Pharmaceuticals
Completed
No outcome recorded
Phase 1/2 4 trials
Phase 1/2
NCT05222165 Oct 2021 → Dec 2022 central nervous system neoplasm , grade II glioma Helsinn Healthcare SA
Withdrawn
No outcome recorded
Phase 1/2
NCT04228042 Jul 2020 → Apr 2024 renal pelvis/ureter urothelial carcinoma M.D. Anderson Cancer Center
Terminated
No outcome recorded
Phase 1/2
NCT02257541 Oct 2014 → Mar 2019 gastrointestinal stromal tumor Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 1/2
NCT02575508 ? → May 2020 colon adenocarcinoma , pancreatic ductal adenocarcinoma , rectum adenocarcinoma Roswell Park Cancer Institute
Withdrawn
No outcome recorded
Phase 2 14 trials
Phase 2
NCT07393373 Apr 2026 → May 2036 expected hypochondroplasia QED Therapeutics, a BridgeBio company
Enrolling by invitation
No outcome recorded
Phase 2
NCT07169279 Nov 2025 → Mar 2030 expected achondroplasia QED Therapeutics, a BridgeBio company
Recruiting
No outcome recorded
Phase 2
NCT05514912 Mar 2024 → Jun 2027 intrahepatic cholangiocarcinoma Emory University
Withdrawn
No outcome recorded
Phase 2
NCT06206278 Oct 2023 → May 2024 gastric cancer , gastroesophageal junction adenocarcinoma LianBio LLC
Terminated
No outcome recorded
Phase 2
NCT05145010 Dec 2021 → Dec 2031 expected achondroplasia QED Therapeutics, a BridgeBio company
Enrolling by invitation
No outcome recorded
Phase 2
NCT05019794 May 2020 → Dec 2022 gastric cancer , gastroesophageal junction adenocarcinoma LianBio LLC
Unknown
No outcome recorded
Phase 2
NCT04265651 Mar 2020 → Oct 2024 achondroplasia QED Therapeutics, a BridgeBio company
Completed
No outcome recorded
Phase 2
NCT04233567 Jan 2020 → Dec 2023 cholangiocarcinoma , metastatic malignant neoplasm Sameek Roychowdhury
Completed
No outcome recorded
Phase 2
NCT03510455 Feb 2019 → Feb 2020 Oncogenic osteomalacia National Institute of Dental and Craniofacial Research (NIDCR)
Terminated
No outcome recorded
Phase 2
NCT02706691 Jun 2018 → Feb 2019 human papilloma virus infection , nasopharyngeal carcinoma , oropharynx squamous cell carcinoma University of Chicago
Terminated
No outcome recorded
Phase 2
NCT02160041 Jul 2014 → Apr 2018 cancer , hematopoietic and lymphoid cell neoplasm Novartis Pharmaceuticals
Terminated
No outcome recorded
Phase 2
NCT02150967 Jul 2014 → Mar 2021 cholangiocarcinoma QED Therapeutics, a BridgeBio company
Terminated
No outcome recorded
Phase 2
NCT02159066 Jul 2014 → Jan 2023 melanoma Pfizer
Completed
No outcome recorded
Phase 2
NCT01975701 Dec 2013 → Oct 2018 malignant glioma Novartis Pharmaceuticals
Completed
No outcome recorded
Show 4 more trials Phase 2/3 1 trial
Phase 2/3
NCT06873035 Apr 2025 → Jan 2027 expected hypochondroplasia QED Therapeutics, a BridgeBio company
Enrolling by invitation
No outcome recorded
Phase 3 3 trials
Phase 3
NCT06164951 Nov 2023 → Dec 2025 achondroplasia QED Therapeutics, a BridgeBio company
Completed
No outcome recorded
Phase 3
NCT04197986 Mar 2020 → Feb 2023 infiltrating bladder urothelial carcinoma , infiltrating renal pelvis/ureter urothelial carcinoma QED Therapeutics, a BridgeBio company
Terminated
No outcome recorded
Phase 3
NCT03773302 Dec 2019 → Mar 2023 cholangiocarcinoma QED Therapeutics, a BridgeBio company
Terminated
No outcome recorded
Phase not applicable 1 trial
— NCT02657486 Jan 2016 → Feb 2026 non-invasive bladder urothelial carcinoma Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded